論文 - 田中 寿志
-
Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia.
Tabe C, Dobashi M, Ishioka Y, Itoga M, Tanaka H, Taima K, Tasaka S.
BMC Res Notes 15 263 2022年07月
-
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S.
2022年06月
-
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.
Thorac Cancer. 2022年05月
-
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.
Makiguchi T, Tanaka H, Taima K, Takayasu S, Tasaka S
Thorac Cancer 13 ( 8 ) 1220 - 1223 2022年04月
-
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report
2022年02月
-
Bilateral Thalamic Lesions Associated With Atezolizumab-Induced Encephalitis: A Follow-up Report With Autopsy Findings.
Nishijima H, Kon T, Seino Y, Yagihashi N, Suzuki C, Nakamura T, Tanaka H, Sakamoto Y, Wakabayashi K, Tomiyama M
Neurology 98 ( 5 ) 204 - 205 2022年02月
-
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K
Cancers 14 ( 2 ) 2022年01月
-
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
Mimori T, Shukuya T, Ko , Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K
Cancers (Basel) 2022年01月
-
Ⅲ各種抗がん薬 22-17. MET阻害薬
田中寿志
新臨床腫瘍学（改訂第7版） 2022年
-
肺癌診療ガイドライン
田中寿志
肺癌診療ガイドライン2022年度版 2022年
-
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H, Hokkaido Lung Cancer Clinical Study Group Trial.
Scientific reports 11 ( 1 ) 23140 - 23140 2021年11月
-
Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S
Thoracic cancer 12 ( 20 ) 2811 - 2814 2021年10月
-
Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S
Thoracic cancer 12 ( 20 ) 2811 - 2814 2021年08月
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients
2021年07月
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.
Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S.
JCSM Clin Rep 2021年07月
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.
Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S
JCSM Clinical Reports 6 103 - 108 2021年07月
-
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N
Thoracic cancer 12 ( 14 ) 2113 - 2121 2021年06月
-
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H, Hokkaido Lung Cancer Clinical Study Group Trial.
Lung cancer (Amsterdam, Netherlands) 156 12 - 19 2021年06月
-
Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung.
Masamichi Itoga, Hisashi Tanaka, Kageaki Taima, Yoshiko Ishioka, Hiroaki Sakamoto, Shingo Takanashi, Akira Kurose, Sadatomo Tasaka
BMC research notes 14 ( 1 ) 25 - 25 2021年01月
-
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka
Cancer communications (London, England) 41 ( 1 ) 83 - 87 2021年01月